EUVIMEDEUVIMED entdecken
Open Access

Albumin binding improves the pharmacokinetics and therapeutic efficacy of a 177 Lu-labeled HER2 Fab radioconjugate

Peifei Liu iD, Yizhen Pang iD, Cuicui Li iD, Yuqi Hua iD, Wenyao Zhen iD, Tianzhi Zhao iD, Xiaobin Zhao iD, Jie Liu iD, Bingyu Li iD, Jinming Yu iD, Xiaoyuan Chen iD, Jingjing Zhang iD

Science Advances · 17.07.2026 · 12 (29)

DOI: 10.1126/sciadv.aee4052 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 17.07.2026. Verfasst von Peifei Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Center for Nuclear Medicine and Molecular Imaging, Shandong Cancer Hospital and Institute, Jinan 250117, China. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Lutetium, Radioisotopes, Albumins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National University of Singapore, Shandong Cancer Hospital, Singapore Ministry of Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Therapeutic antibodies and antibody-drug conjugates are limited by large molecular size, poor tumor penetration, and signaling-adaptive resistance. We introduce an engineering strategy for radiotherapeutic antibody fragments in which an albumin-binding domain (ABD) rebalances molecular size and pharmacokinetics. Using human epidermal growth factor receptor 2 (HER2) as a proof of concept, we developed 177 Lu-DOTA-Fab-ABD, which integrates rapid tumor penetration with albumin-mediated extended circulation, improving tumor dosimetry while reducing off-target radiation. In HER2 tumor models, 177 Lu-DOTA-Fab-ABD showed strong HER2 and albumin binding, reduced off-target retention, and substantially lower hematologic toxicity than full-length 177 Lu-DOTA-pertuzumab while maintaining potent β-particle tumor control. It also overcame intrinsic trastuzumab resistance by bypassing receptor blockade and inducing DNA double-strand breaks and displayed mechanistic complementarity with trastuzumab. Overall, 177 Lu-DOTA-Fab-ABD represents a generalizable framework for engineering fragment–based radiotherapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesLutetiumRadioisotopesAlbuminsImmunoconjugatesImmunoglobulin Fab FragmentsRadiopharmaceuticalsHumansAnimalsMiceTrastuzumabCell Line, TumorFemaleAntibodies, Monoclonal, HumanizedXenograft Model Antitumor AssaysProtein Binding

Substanzen

Erb-b2 Receptor Tyrosine KinasesLutetiumRadioisotopesTrastuzumabERBB2 protein, humanLutetium-177Antibodies, Monoclonal, HumanizedAlbuminsImmunoconjugatesImmunoglobulin Fab Fragments

Autor:innen und Institutionen

  • Center for Nuclear Medicine and Molecular Imaging, Shandong Cancer Hospital and Institute, Jinan 250117, China.
  • Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen 361102, China.
  • Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119074, Singapore.
  • Theranostics Center of Excellence, Yong Loo Lin School of Medicine, National University of Singapore, 11 Biopolis Way, Helios, Singapore 138667, Singapore.
  • Clinical Imaging Research Centre, Centre for Translational Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117599, Singapore.
  • Department of Nuclear Medicine, Affiliated Hospital of Jiangnan University, No. 1000, Hefeng Road, Wuxi 214028, China.

ORCID-Profile: Peifei Liu, Yizhen Pang, Cuicui Li, Yuqi Hua, Wenyao Zhen, Tianzhi Zhao, Xiaobin Zhao, Jie Liu, Bingyu Li, Jinming Yu, Xiaoyuan Chen, Jingjing Zhang

Förderung

  • National University of Singapore
  • Shandong Cancer Hospital
  • Singapore Ministry of Education
  • Taishan Scholar Program

Zitieren

APA

Liu, P., Pang, Y., Li, C., Hua, Y., Zhen, W., Zhao, T., Zhao, X., Liu, J., Li, B., Yu, J., Chen, X., & Zhang, J. (2026). Albumin binding improves the pharmacokinetics and therapeutic efficacy of a 177 Lu-labeled HER2 Fab radioconjugate. Science Advances, 12(29). https://doi.org/10.1126/sciadv.aee4052

Vancouver

Liu P, Pang Y, Li C, Hua Y, Zhen W, Zhao T, et al. Albumin binding improves the pharmacokinetics and therapeutic efficacy of a 177 Lu-labeled HER2 Fab radioconjugate. Science Advances. 2026;12(29). doi:10.1126/sciadv.aee4052

BibTeX
@article{Liu2026,
  author = {Liu, Peifei and Pang, Yizhen and Li, Cuicui and Hua, Yuqi and Zhen, Wenyao and Zhao, Tianzhi and Zhao, Xiaobin and Liu, Jie and Li, Bingyu and Yu, Jinming and Chen, Xiaoyuan and Zhang, Jingjing},
  title = {Albumin binding improves the pharmacokinetics and therapeutic efficacy of a 177 Lu-labeled HER2 Fab radioconjugate},
  journal = {Science Advances},
  year = {2026},
  volume = {12},
  number = {29},
  doi = {10.1126/sciadv.aee4052}
}
Kostenlos starten →